A Single-Arm, Phase II Clinical Study of Sintilimab and Bevacizumab Combined With Pemetrexed and Cisplatin for Unresectable Malignant Peritoneal Mesothelioma.

The article focuses on a single-arm, Phase II clinical study designed to evaluate the efficacy and safety of a combination treatment involving sintilimab, bevacizumab, pemetrexed, and cisplatin for patients with unresectable malignant peritoneal mesothelioma. It aims to measure Progression-Free Survival (PFS) as the primary outcome, while secondary outcomes include Overall Survival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR).